University of Manitoba scored a “C+” on the University Global Health Impact Guide. Learn why and see how other schools compare.

                                                                                                                                                                                                                                                                                                                                                                                                                                                                               

University of Manitoba

Posted on September 25 2017 by admin

Total

Grand Total Score: 59.75 (out of XXX?) Grand Total Grade: C+

Innovation

Total Score: 37.5
Grade: B+

IQ1

Q

What percentage of the university's total biomedical research funding received from CIHR, NSERC, and the Gates Foundation is devoted to projects focused on neglected diseases (NDs), neglected aspects of HIV/AIDS, Tuberculosis, Malaria, and/or antimicrobial resistance (AMR)?

A
48.24%
7.5 (out of 7.5)

IQ2

Q

What percentage of the university's total medical research funding is devoted to projects focused on neglected diseases?

A
7.62%
7.5 (out of 7.5)

IQ3

Q

What percentage of the university’s total medical PubMed publications is focused on global health?

A
4.16%
4 (out of 5)

IQ4

Q

What percentage of the university’s total medical PubMed publications is focused on neglected diseases, neglected aspects of HIV, TB, malaria, antimicrobial resistance, and/or access to medicines in low- and middle-income countries?

A
6.54%
5 (out of 5)

IQ5

Q

Does the university have a research center or institute dedicated specifically to neglected diseases and/or neglected aspects of HIV/AIDS, TB, Malaria, or AMR?

A

None of the above

0 (out of 12.5)

IQ6

Q

How many Grand Challenges Canada grants has the university been awarded between FY2013 and present?

A

4

6 (out of 7.5)

IQ7

Q

In the wake of the current Zika epidemic, how has your institution responded to the lack of innovation that currently exists for prevention, diagnosis and/or treatment of this disease? [WRITTEN SURVEY RESPONSE NOT GRADED]

IQ8

Q

Is any of the university’s medical research being done in collaboration with, funded by or driven by alternative models for research and development? (e.g Drug Discovery and Data-Sharing platforms, Prizes, Philanthropy for Drug Discovery, Drug Patent Pools, Public-Private-Partnerships etc.)

A

None of the above

0 (out of 12.5)

IQ9

Q

Is the University currently engaged in or supporting research on Canadian drug pricing mechanisms to ensure equitable access to affordable medicines, or has research in this area been carried out in the past 2 years?

A

Publication(s)

7.5 (out of 12.5)

IQ10

Q

Is the university currently in one or more partnerships with a pharmaceutical corporation either via a specific research project, lab, center, initiative, or other model? [WRITTEN SURVEY RESPONSE NOT GRADED]

Access

Total Score: 10.5
Grade: C-

AQ1

Q

Has the university officially and publicly committed to licensing its medical discoveries in ways that promote access and affordability for resource-limited populations?

A
No
0 (out of 5)
Q

Does the website of the university's technology transfer office (TTO) make an effort to disclose, explain and promote access licensing commitments and practices?

A
No
0 (out of 5)

AQ2

Q

Has the university officially and publicly committed to licensing its medical discoveries in ways that promote access and affordability for resource-limited populations?

A

There is a university-wide policy on open-access publications that is actively being implemented

2 (out of 5)
Q

Does the university provide support for open access publishing?

A

Yes, there are informal mechanisms to support and encourage open access publishing.

1 (out of 5)
Q

What percentage of the university's total medical sciences publication output is published in open-access publications?

A
31-50%
1.5 (out of 5)

AQ3

Q

In 2011, what percentage of the university's total research licenses were non-exclusive?

A
0%
0 (out of 5)
Q

In the past year, what percentage of the university's health technology licenses were non-exclusive?

A
0%
0 (out of 5)

AQ4

Q

In the past year, for what percentage of all health technologies did the university seek patents in developing countries where they may restrict access?

Q

Brazil, Russia, India, China, or South Africa

A
No Data
0 (out of 5)
Q

All other Lower and Lower-Middle Income Countries

A
No Data
0 (out of 5)

AQ5

Q

In the past year, what percentage of the university’s exclusive licenses of health technologies included provisions to promote access to those technologies in developing countries?

A
No Data
0 (out of 5)
Q

What percentage of those access provisions included the biggest developing-world economies (Brazil, Russia, India, China or South Africa) in their scope?

A
No Data
0 (out of 5)
Q

In the past year, what percentage of the university’s exclusive licenses of health technologies included provisions to promote access to those technologies in high-income countries?

A
No Data
0 (out of 5)

AQ6

Q

Has the university shared its best practices for promoting access to treatment through licensing?

Options:

● Contributed sample clauses to the AUTM Global Health Toolkit

● Published an article on access licensing practices

● Formally presented on access licensing practices at an academic or professional event, or at another university

● Informally shared or discussed access licensing practices with administrators at other universities

● Other

A
No Data
0 (out of 5)

AQ7

Q

Has the university publicly acknowledged the existence/effectiveness of alternative models of research and development as being important to ensuring access to medical innovation?

Options:

● Publicly written statement of intent or explanation on official university or TTO website

● Published an article on alternative research and development

● Formally presented alternative R&D models at an academic or professional event, or at another university

● Informally shared or discussed alternative approaches to R&D with administrators at other universities

● Other

A
0
0 (out of 5)

AQ8

Q

Between January 2006 and December 2014, what percentage of completed clinical trials registered on ClinicalTrials.gov conducted by the university had their data shared as summary results on ClinicalTrials.gov or pubmed?

A
33.30%
6 (out of 5)

Empowerment

Total Score: 8.75
Grade: C-

EQ1

Q

Does the university offer its students access to global health engagement and/or education?

Q

As indicated by the existence of a university center/institute, department, and/or non-degree program in global health.

A
A global health center/institute & at least one global health initiative or non-degree program
8 (out of 10)
Q

As indicated by the existence of a university graduate degree, major/concentration, focus/specialization, certificate, and/or other academic track in global health.

A
No global health degree, academic track or certificate
0 (out of 10)

EQ2

Q

Does the university offer graduate courses that address the policy and legal context of biomedical R&D, and more specifically the impact of intellectual property policies on research priorities and global access to medical innovations?

A
No
0 (out of 5)

EQ3

Q

Does the university offer graduate courses that address the prevalence of and/or lack of research on neglected diseases, including neglected aspects of HIV, TB, and/or malaria?

A
No
0 (out of 5)

EQ4

Q

Has the university recently hosted a conference, symposium or campus-wide event on the topics of A) impact of intellectual property on global access to medicines or B) neglected diseases and health needs of developing countries?

A
No events hosted
0 (out of 5)

EQ5

Q

Does the university offer any of its students accessible opportunities to study, work, or complete research abroad in global health?

A
1 offering (Global Health funding in grants, scholarship, awards, fellowships), 0 offerings (Global Health study abroad scholarships and fellowships)0 offerings (Global Health study abroad scholarships and fellowships), 1 offering (Global Health practicum opportunities), 0 offerings (Engagement in Global Health Clinics abroad)
0.8 (out of 5)

EQ6

Q

Is the university formally involved in a global health partnership with one or more universities based in low- and middle-income countries? [WRITTEN SURVEY RESPONSE NOT GRADED]

EQ7

Q

Does the university offer any of its students an opportunity to learn more about alternative models for research and development through courses, workshops, or other opportunities?

A
None of the above
0 (out of 5)

Transparency

Total Score: 3
Grade: C-

TQ1

Q

How responsive was the university's Technology Transfer Office (TTO) to emails from UAEM regarding the Innovation and Access sections surveys?

A

No response received throughout entire Data Collection period

0 (out of 5)

TQ2

Q

For questions relying on public data (CATEGORY 1) in the Access section, was sufficient information available online?

A
Data found for half of total questions
1 (out of 5)
Q

For questions relying on public data (CATEGORY 1) in the Innovation section, was sufficient information available online?

A
Data found for more than half of total questions
1.5 (out of 5)
Q

For questions relying on public data (CATEGORY 1) in the Empowerment section, was sufficient information available online?

A
Data found for less than half of total questions
0.5 (out of 5)

TQ3

Q

How much discrepancy exists between university responses in the submitted forms and what is being internally collected using publicly available data for Category 1 and 2 questions?

A
More than 50% of questions contain discrepancies
0 (out of 5)

TQ4

Q

Does the university have clear guidelines for conflict of interest policies delineated for partnerships with industry that have commercial interest? [WRITTEN SURVEY RESPONSE NOT GRADED]